|1.||Kamal, Ahmed: 9 articles (11/2015 - 11/2003)|
|2.||Chen, Hong: 5 articles (03/2015 - 02/2010)|
|3.||Cao, Bo: 4 articles (03/2015 - 02/2010)|
|4.||Suresh, Paidakula: 4 articles (09/2013 - 12/2010)|
|5.||Bailly, Christian: 4 articles (04/2012 - 02/2006)|
|6.||Behmanesh, Mehrdad: 3 articles (01/2015 - 03/2012)|
|7.||Srinivasa Reddy, T: 3 articles (10/2014 - 09/2013)|
|8.||Shankaraiah, Nagula: 3 articles (10/2014 - 09/2013)|
|9.||Qi, She-Ning: 3 articles (06/2013 - 07/2007)|
|10.||Li, Guo-feng: 3 articles (06/2011 - 05/2007)|
08/01/2003 - "When subjects defaulting from follow up were assumed not to have been cured odds of remission of all warts were significantly increased for podophyllotoxin solution (OR 1.92, 95% CI 1.13 to 3.27), but not for podophyllotoxin cream (OR 1.17, 95% CI 0.69 to 2.00). "
08/01/2003 - "When subjects defaulting from follow up were assumed to have been cured odds of remission of all warts were also significantly increased both for podophyllotoxin solution (OR 3.04, 95% CI 1.68 to 5.49) and for podophyllotoxin cream (OR 2.46, 95% CI 1.38 to 4.40). "
04/01/1994 - "When analysing the debulking potential of podophyllotoxin, it appeared that 0.25% podophyllotoxin eradicated 184 of originally 217 warts (85%); the corresponding figure for 0.50% podophyllotoxin was as high as 130 of 135 lesions (96%). "
05/01/1990 - "Podofilox 0.5% solution is effective in treating penile warts and is well tolerated in a self-administered regimen. "
01/01/1998 - "To determine the safety and efficacy of a new gel formulation of podofilox in the treatment of anogenital warts. "
|2.||Condylomata Acuminata (Genital Wart)
02/01/1995 - "In the therapeutic arsenal for the treatment of condylomata, podophyllotoxin 0.5% is a first line treatment for condylomata acuminata of the genital mucous membranes."
10/01/1990 - "Thus, 0.5% podofilox solution appears to be an effective treatment for condylomata acuminata, with acceptable side effects that are local and temporary."
12/01/1990 - "In conclusion podophyllotoxin 0.5% appeared to be safe and effective for the self treatment of genital warts."
01/01/1993 - "The purpose of this comparative open study was to determine the clinical efficacy of 0.3% podophyllotoxin both in 70% ethanolic solution and cream preparations on genital warts. "
12/01/1995 - "To evaluate the clinical efficacy of a 0.15% and a 0.3% cream formulation of podophyllotoxin in comparison with the 0.5% solution in the treatment of condylomata acuminata and to compare the treatment modalities regarding side effects. "
10/01/2012 - "Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells."
03/01/2010 - "In order to overcome these limitations, it is essential to search new podophyllotoxin analogues with improved anticancer activity and fewer side effects to gain the maximum benefits for the cancer patients. "
11/01/2015 - "In our previous studies 4β-cinnamido linked podophyllotoxin conjugates were synthesized and evaluated for their cytotoxic activity in a panel of five human cancer cell lines and the new molecules like 17a and 17f were considered as potential leads. "
03/01/2015 - "In this study, we aimed to investigate CIP-36, a novel podophyllotoxin derivative, for its inhibitory effects on human cancer cells from multiple sources, particularly cells with MDR in vitro. "
03/21/2014 - "To extend our prior studies in this research area, we synthesized a new generation of spin-labeled podophyllotoxin analogs via isocyanide multicomponent reactions and evaluated their cytotoxicity against four human cancer cell lines (A-549, DU-145, KB and KBvin). "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/01/1995 - "Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases."
01/01/1982 - "Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia."
10/01/1998 - "High cumulative epipodophyllotoxin dosages are reported to be associated with an elevated risk for secondary acute myeloid leukemia (s-AML). "
03/01/1997 - "Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia."
10/01/1995 - "The risk for induction of epipodophyllotoxin-related acute myeloid leukemia (AML) depends largely on the schedule of drug administration and, to a lesser degree, the cumulative dose. "
06/01/2015 - "Cytotoxic activity of podophyllotoxin and selected leaf extracts of Juniperus sp. against a set of leukemia cell lines was demonstrated."
06/01/2015 - "Podophyllotoxin IC50 cytotoxicity values against J45.01 and CEM/C1 leukemia cell lines were 0.0040 and 0.0286 µg/mL, respectively. "
01/01/2014 - "Compound A398, a novel podophyllotoxin analogue: cytotoxicity and induction of apoptosis in human leukemia cells."
12/01/2010 - "Whatever the model, we failed to evidence a role for the radiation dose to active bone marrow in the risk of later leukemia, myelodysplasia, or myeloproliferative syndrome, when adjusting for epipodophyllotoxin and anthracycline doses. "
02/01/2010 - "Reversal of mdr1-mediated multidrug resistance in human leukemia cells by a new spin-labeled derivative of podophyllotoxin."
|3.||Etoposide (VP 16)
|4.||Teniposide (VM 26)
|6.||etoposide phosphate (Etopophos)
|8.||Ethanol (Ethyl Alcohol)
|9.||Salicylic Acid (2 Hydroxybenzoic Acid)
|10.||Granulocyte Colony-Stimulating Factor (G-CSF)
|1.||Drug Therapy (Chemotherapy)
|2.||Laser Therapy (Surgery, Laser)